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Unacylated Ghrelin Promotes Skeletal Muscle Regeneration Following
Hindlimb Ischemia via SOD-2–Mediated miR-221/222 Expression
Gabriele Togliatto, BS;* Antonella Trombetta, BS, PhD;* Patrizia Dentelli, BS; Paolo Cotogni, MD, ChB; Arturo Rosso, ST;
Matthias H. Tsch€op, MD, PhD; Riccarda Granata, BS, PhD; Ezio Ghigo, MD; Maria F. Brizzi, MD, PhD
Background-—Surgical treatment of peripheral artery disease, even if successful, does not prevent reoccurrence. Under these
conditions, increased oxidative stress is a crucial determinant of tissue damage. Given its reported antioxidant effects, we
investigated the potential of unacylated-ghrelin (UnAG) to reduce ischemia-induced tissue damage in a mouse model of peripheral
artery disease.
Methods and Results-—We show that UnAG but not acylated ghrelin (AG) induces skeletal muscle regeneration in response to
ischemia via canonical p38/mitogen-actived protein kinase signaling UnAG protected against reactive oxygen species–induced cell
injuries by inducing the expression of superoxide dismutase-2 (SOD-2) in satellite cells. This led to a reduced number of infiltrating
CD68+ cells and was followed by induction of the myogenic process and a reduction in functional impairment. Moreover, we found
that miR-221/222, previously linked to muscle regeneration processes, was up-regulated and negatively correlated with p57Kip2
expression in UnAG-treated mice. UnAG, unlike AG, promoted cell-cycle entry in satellite cells of mice lacking the genes for ghrelin
and its receptor (GHSR1a). UnAG-induced p38/mitogen-actived protein kinase phosphorylation, leading to activation of the
myogenic process, was prevented in SOD-2–depleted SCs. By siRNA technology, we also demonstrated that SOD-2 is the
antioxidant enzyme involved in the control of miR-221/222–driven posttranscriptional p57Kip2 regulation. Loss-of-function
experiments targeting miR-221/222 and local pre–miR-221/222 injection in vivo confirmed a role for miR-221/222 in driving
skeletal muscle regeneration after ischemia.
Conclusions-—These results indicate that UnAG-induced skeletal muscle regeneration after ischemia depends on SOD-2–induced
miR-221/222 expression and highlight its clinical potential for the treatment of reactive oxygen species–mediated skeletal muscle
damage. ( J Am Heart Assoc. 2013;2:e000376 doi: 10.1161/JAHA.113.000376)
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P eripheral artery disease (PAD) is a widespread conditioncaused by atherosclerosis of the peripheral arteries.1
Diabetes and obesity are major risk factors for PAD and its
associated complications.2 Although surgical or endovascular
intervention remains the standard therapy to improve blood
flow,3 even after successful revascularization, most patients
complain of persistent or recurring symptoms.4 Consequently,
in an aging population with an increasingly high incidence of
metabolic disease, new treatment options for PAD represent a
major unmet need.
In PAD, reduced blood supply to the ischemic limb leads to
skeletal muscle injury.5 In response to tissue damage, resident
stem cells, the satellite cells (SCs), are recruited and
participate in regenerative processes.6 On ischemia, SCs
undergo asymmetric division7 that gives rise to cells that enter
the cell-cycle via p38/mitogen-activated protein kinase
(MAPK) activation and myogenic differentiation antigen D
(MyoD) induction8 and daughter cells that lack p38/MAPK-
mediated signals and refill the SC pool.9 In addition to the role
of MyoD and the regulatory myogenic factor 5 (Myf5),
posttranscriptional regulation, involving small noncoding
micro-RNAs (miRs), is known to play a role in skeletal muscle
regeneration.10–12 Different families of miRs, including miR-
221/222, have been shown to be involved in the control of a
complex network of genes during myogenesis.13,14
Changes in local oxygen availability in PAD result in
increased numbers of dysfunctional mitochondria.5,15 Defec-
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tive mitochondrial electron transfer chain and increased
reactive oxygen species (ROS) generation are crucial deter-
minants of oxidative damage and impaired cellular func-
tions16–19 that ultimately lead to muscle damage.20
Interestingly, superoxide dismutase-2 (SOD-2), the initial line
of defense against ROS in the mitochondria, is deficient in
PAD muscles.5 Consistent with this observation, antioxidant
administration ameliorates skeletal muscle mitochondrial
dysfunction and functional recovery in humans.21 Thus,
molecules that exert protective effects against oxidative
stress might represent an alternative therapeutic strategy to
preserve skeletal muscle function in PAD.
In this study, we investigate the potential therapeutic use of
unacylated ghrelin (UnAG) for the treatment of PAD. Ghrelin is
present in the circulation in both acylated (AG) and unacylated
(UnAG) forms.22 The term “ghrelin” has traditionally been used
to refer only to AG, which has been considered the only active
peptide form. It binds to the Gq-coupled growth hormone (GH)
secretagogue receptor type 1a (GHSR1a)23 and mediates GH-
releasing properties and other significant neuroendocrine
actions.24 In contrast, UnAG does not bind to GHSR1a and
lacks GH-secretagogue activity.24 AG and UnAG have been
shown to exert effects on muscle and vascular cell differenti-
ation through a common receptor.25–27 However, clinical
studies have shown that UnAG and AG exhibit opposing
metabolic actions.28,29 Similarly, UnAG and AG induce different
biological responses in neonatal mouse and rat cardiomyo-
cytes,30 and only UnAG protects endothelial progenitor cells
from oxidative stress by avoiding ROS generation.31,32 This
protective effect occurs via a receptor not shared with AG.31
Thus, clinical28,29 and experimental30,31 data suggest the
existence of an additional unidentified receptor for UnAG.
Here, we evaluated the effects of UnAG and AG on skeletal
muscle regeneration in a mouse model of PAD.
Methods
Reagents were obtained as follows. Collagen I, collagenase II,
FCS, FBS, RNase, propidium iodide, SDS, PIPES, Triton
X-100, Nonidet P-40, NaCl, NaF, NaOV4, Na4P2O7, MgCl2,
KCl, HCl, Na-azide, Tris, EDTA, EGTA, ethanol, aprotinin, PMSF,
DTT, leupeptin, penicillin-streptomycin, HEPES, tribromoethyl-
alcohol (Avertin), barium chloride (BaCl2), chicken embryo
extract (CEE), RPMI, and DAPI were from Sigma-Aldrich.
Collagenase/dispase was from Roche. Protein molecular
weight markers, acrylammide, and polyvinylidene difluoride
(PVDF) membranes were from Bio-Rad. Gene Ruler DNA
Ladder Mix and Gene Ruler DNA Ladder Plus were from
Fermentas International Inc. Nylon mesh cell strainer
(100 lm, 70 lm, 40 lm) was from BD Bioscience Pharmin-
gen. SB202190, p38/MAPK substrate inhibitor, and Akt
inhibitor VI (TCL110-24, H-AVTDHPDRLWAWEKF-OH) were from
Calbiochem. c-Met inhibitor (Crizotinib) was from Selleck
Chemicals. AG and UnAG were from Phoenix Pharmaceuti-
cals. D-PBS, Optifect, Lipofectin Reagent, TRIzol, DMEM, and
DCF-DA were from Invitrogen (Life Technologies). Antibodies
were obtained as follows. Monoclonal anti-PCNA was from
Abcam. Anti-CD31 and -CD68 were from BD Bioscience
Pharmingen. Anti-MyoD, anti-p57Kip2, anti-p27Kip1, anti–SOD-
2, anti-myogenin, anti-Myf5, anti-p38/MAPK, anti–Pax-7, and
anti–Pax-3 were from Santa Cruz Biotechnology. Anti–
phospho-p38/MAPK, anti–phospho Akt, anti-Akt, anti-rabbit
IgG, HRP linked, and anti-mouse IgG, HRP linked, were from
Cell Signaling. Anti–a-actin, anti-tubulin, and anti-mouse,
-rabbit, and -goat IgG-FITC and -PE were from Sigma-Aldrich.
Murine Hindlimb Ischemia Model
Male C57BL/6J mice (Charles River Laboratories International
Inc) were anesthetized by intra-peritoneal administration of
tribromoethanol (Avertin) (375 to 425 mg/kg), and unilateral
hindlimb ischemia was induced as described.33 The entire
femoral artery and vein of the right hindlimb were exposed
and isolated (inguinal ligament to its bifurcation into saphe-
nous and popliteal artery). Exposed vessels were ligated at
their proximal and distal ends (poplitea ramification), and both
vessels were excised. The normo-perfused contralateral limb
of each mouse was used as an internal control.
After hindlimb ischemia, animals (27 mice per group) were
treated via intraperitoneal injection daily from days 0 to 21
with either saline, AG (100 lg/kg), or UnAG (100 lg/kg). In
selected experiments, C57BL/6J mice received intramuscular
injections of pre-miR oligonucleotides (5 mice/group), and
Balb/c mice (Charles River Labs; 3 mice/group) were treated
via daily intraperitoneal injection with either saline, AG
(100 lg/kg), or UnAG (100 lg/kg) from days 0 to 21 after
the induction of ischemia. To induce toxic damage, 100 lL of
1% BaCl2 was injected unilaterally into the hindlimb at day 0
(9 mice), and the mice were killed 48 hours later. Within each
group, some animals were killed at days 1, 3, 5, and 7 and the
remainder at day 21. Gastrocnemius muscles were dissected
and processed as described here later. Mice were treated
according to European guidelines and policies as approved by
the University of Turin Ethical Committee.
Laser Doppler Perfusion Imaging
Mice were anesthetized as described here, and hair was
removed using an electric shaver. Serial, noninvasive assess-
ment of ischemic limb microvascular perfusion was performed
in triplicate and in a blinded manner using the laser Doppler
Perfusion Imaging system (PIM3; Perimed). Identical regions,
equal in area, encompassing the distal leg (entire foot) of both
ischemic and contralateral, nonischemic limbs were assessed
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for quantification of perfusion using the laser Doppler
perfusion imaging processing software (version 5.0).
In Vivo Assessment of Limb Function
Semiquantitative estimation of foot damage (by repeated-
measures ANOVA and Newman–Keuls multiple-comparisons
test) was performed serially using the following classification:
3=dragging of foot (foot necrosis), 2=no dragging but no
plantarflexion (foot damage), 1=plantarflexion but no toe
flexion (toe damage), and 0=flexing the toes to resist gentle
traction on the tail (no damage).34
Histological and Immunofluorescence Analysis
Gastrocnemius muscles were recovered from ischemic and
normo-perfused limbs of treated animals, fixed in 10% formalin,
and embedded in paraffin. Tissue sections (5 lm) were stained
with hematoxylin and eosin for histological analysis. The
proportion of fibers with central nuclei (regenerating fibers)
was counted in the injured area and the cross-sectional areas of
the fibers in the injured and noninjured areas. Measurements
were obtained using the MetaMorph software (Life Sciences
Research Imaging Systems). For immunofluorescence assay,
muscle sections were processed as described previously35
using anti-CD68, anti–SOD-2, anti-myogenin, anti-MyoD, anti-
CD31, and anti–Pax-7 antibodies. DAPI was used as a nuclear
marker. To quantify cells expressing the indicated markers,
positive cells were counted in 10 randomly selected fields in 5
different samples (940 magnification). The number of CD31+
vessels was evaluated by counting 10 randomly selected fields
in 3 different samples (940 magnification). Images were
acquired with a Zeiss LSM 5 Pascal confocal laser-scanning
microscope (Carl Zeiss) equipped with a helium/neon laser
(543 mm), an argon laser (450 to 530 mm), and an EC planar
Neofluar 940/1.3 oil-immersion differential interference con-
trast objective lens. Images were analyzed using Zeiss LSM 5
version 3.2 software.35
Cell Cultures and In Vitro Ischemia
SCs were isolated from gastrocnemius muscles subjected to
ischemia. In selected experiments, SCswere also recovered from
10- to 12-week-old male C57BL/6J mice lacking the GH
secretagogue receptor 1 and ghrelin genes (double-knockout
mice) (10 mice, the kind gift of Professor M. Tsch€op).36 To
obtain SCs, muscle samples were subjected to enzymatic
digestion using collagenase type II (0.1 mg/mL) in DMEM for
20 minutes at 37°C and then collagenase/dispase (1 mg/mL)
in DMEM for 30 minutes at 37°C, as described previously.37
After centrifugation at 30 g at 4°C for 10 minutes, the pellet was
washed with DMEM and recentrifuged at 160 g at 4°C for
10 minutes. The pellet was then passed through a graduated
series of nylon mesh cell strainers (100, 70, and 40 lm) to
separate mononuclear cells from muscle fibers and myofibril
fragments. The resulting supernatants were centrifuged at 160 g
for 10 minutes and cells were preplated for 1 hour in a
humidified CO2 incubator at 37°C to remove fibroblasts, as
described elsewhere.37 This adhering/detachment procedure
was repeated twice to remove residual fibroblasts. Purified SCs
were then plated at 2.59104 cells/cm2 and cultured on collagen
I–coated dishes with DMEM supplemented with 20% FBS, 3%
chick embryo extract, 1% penicillin-streptomycin, and HEPES
(10 nmol/L). Murine C2C12 cells (Istituto Zooprofilattico
Sperimentale della Lombardia e dell’Emilia) were cultured in
DMEM supplemented with 10% FBS, 1% penicillin-streptomycin.
COS-7 cells were cultured in RPMI supplemented with 10% FBS,
1% penicillin-streptomycin. In selected experiments, SCs, recov-
ered from normo-perfused muscles, and COS-7 and C2C12 cells
were treated for 3 days with saline, AG (1 lmol/L), or UnAG
(1 lmol/L), or with the retro-des-acyl ghrelin peptide (1–14),32
which was used as a negative control (1 lmol/L, scramble
peptide). At day 4, cells were subjected to in vitro ischemia. In
vitro ischemia was induced by incubating cells in DMEM+2% FCS
at 5% CO2/95% N2 humidified atmosphere, yielding 1% O2
concentrations for 24 hours.18 Where indicated, in vitro ische-
mia was also performed in the presence of the specific inhibitor
of p38/MAPK SB202190 (1 lmol/L), the specific Akt inhibitor
TCL110-24 (100 nmol/L), or Crizotinib (1 lmol/L),
38 an inhibitor
of mesenchymal-epidermal transition (c-Met) receptor tyrosine
kinase. Crizotinib was added to SCs 1 day before the indicated
treatments.
Cell-Cycle Progression and Proliferation
Cell-cycle progression of SCs was evaluated by FACS analysis,
as described previously.39 The percentage of cells in each
cell-cycle phase was determined using ModFit LT software
(Verity Software House, Inc). Cell proliferation was also
assayed by evaluating the percentage of PCNA+ cells by FACS
analysis.
Western Blot Analysis
Cells were lysed (50 mmol/L Tris-HCl [pH 8.3], 1% Triton X-100,
10 mmol/L PMSF, 100 U/mL aprotinin, 10 lmol/L leupeptin)
and protein concentrations were obtained as previously
described.40 Proteins (50 lg) were subjected to SDS-PAGE,
transferred onto nitrocellulose membranes, blotted with the
indicated antibodies, and revealed using an enhanced chemi-
luminescence detection system (ECL). Densitometric analysis
was used to calculate the differences in the fold induction of
protein levels and normalized to tubulin, a-actin, Akt, or
p38MAPK content. Values are reported as relative amount.
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Oxidative Stress Measurement
Intracellular ROS production was evaluated using the DCF-DA
(5- [and 6-]carboxy-2′,7′-dichlorofluorescein diacetate, 0.5 lmol/L
final concentration; Molecular Probe, Invitrogen) assay. The
majority of experiments were performed after 2 hours of the
indicated treatments, as previously described.31 Thiobarbituric
acid reactive substances (TBARS) were evaluated to measure in
vivo oxidative stress levels in gastrocnemius muscles. The
formation of TBARS was determined using the OXI-TEK kit
(ZeptoMetrix Corp) and a luminescence spectrometer (Bio-Rad
Laboratories) with excitation set at 530 nm and emission at
550 nm.19
RNA Isolation and Quantitative Real-Time PCR
(qRT-PCR) for miRNAs
Total RNA was isolated using TRIzol reagent (Invitrogen) from
SCs recovered from the muscles of treated animals or from
SCs subjected to in vitro ischemia. The RNA was then reverse-
transcribed using a TaqMan microRNA RT kit specific for miR-
221 and miR-222, and subjected to quantitative real-time PCR
using TaqMan microRNA assay kit and the ABI PRISM 7700
sequence detection system (Applied Biosystems).41 Expres-
sion of miRNAs was normalized to the small nuclear RNA
RNU6B. Loss-of-function experiments were performed in
saline- or UnAG-treated SCs transfected for 48 hour with
anti-miRNA negative control, anti–miR-221, or anti–miR-222
antagonists (Applied Biosystem), according to the manufac-
turer’s instructions.41
SOD-2 Silencing by Small Interfering RNAs
To obtain SOD-2 inactivation, SCs were transiently transfected
with small interfering RNA (siRNA) for SOD-2 or with duplex
siRNAs (Qiagen) and treated as indicated. Transfection was
performed according to the manufacturer’s instructions. Whole
cell extracts were processed 48 hours after transfection. Cell
viability was evaluated at the end of each experiment.35
Luciferase miRNA Target Reporter Assay
The luciferase reporter assay was performed using a construct
generated by subcloning the PCR products amplified from the
full-length 3′-UTR of p57Kip2 DNA into the SacI restriction site
of the luciferase reporter vector pmiR (Ambion, Applied
Biosystem). The PCR products were obtained using the
following primers: p57Kip2: sense, 5′-TTGAGCTCCCCTTCTTCT
CGCTGTCCTCT-3′; antisense, 5′-AAGAGCTCCTCTTTGGGCTC
TAAATTGGC-3′. The insert identities were verified by sequenc-
ing. The pmiR empty vector and pmiR-3′-UTR p57Kip2 reporter
vector were transiently co-transfected in SCs subjected to in
vitro ischemia and treated as indicated at a 30:1 molar ratio
with the pRL vector, coding for the Renilla luciferase, used as
an internal control for the luciferase assay.40
In Vivo Gain-of-Function Analysis
To evaluate the effects of miR-221/222 expression in vivo, a
combination of pre–miR-221 and pre–miR-222 or pre-miR
negative control (50 lL of 50 nmol/L stock solution of pre-miR
oligonucleotides added to 12 lL of Optifect [Invitrogen]) was
injected directly into the ischemic gastrocnemius muscle of
C57BL/6Jmice. Pre-miRsor controlswereadministered3 timesa
week. At day 7, animals were killed, and tissues were recovered
and processed as described earlier for histological analysis. SCs
were also isolated and evaluated byWestern blot for the indicated
markers and by quantitated real-time PCR for miRNA expression.
Statistical Analysis
All data are presented as meanSEM. The D’Agostino–Pearson
test was used to test normality. Data on blood perfusion,
damage score, number of vessels, percentage of regenerating
fibers, inflammatory cells, recovery of SCs, Pax7/MyoD co-
localization, TBARS, miR-221/222, and p57Kip2/p27Kip1
expression from ischemic and nonischemic limbs of treated
mice at days 7 and 21were analyzed by using the 2-way ANOVA
followed by the post-hoc test with Bonferroni correction for
multiple comparison. Data on myogenin expression, ROS
generation, Pax-7/SOD-2 co-localization, percentage of cell-
cycle phases, PCNA expression, luciferase assay, and miR-
221/222 expression in in vitro or in gain-of-function experi-
ments were analyzed with 1-way ANOVA followed by Tukey’s
multicomparison post-hoc test. Data on densitometric analysis
for Western blots were analyzed by Student t test for 2-group
comparison and by 1-way ANOVA, followed by Tukey’s multiple
comparison test for ≥3 groups.
The cut-off for statistical significance was set up at P<0.05
(*P<0.05, **P<0.01, ***P<0.001). All statistical analyses
were carried out with GraphPad Prism version 5.04 (Graph
Pad Software, Inc).
Results
UnAG Protects Skeletal Muscles Against
Ischemia-Induced Functional Impairment
Unilateral hindlimb ischemia, which mimics critical limb
ischemia (CLI) in humans, was induced in C57BL/6J mice,
and mice were treated daily with saline, AG, or UnAG,
beginning at day 0 and ending at day 21. Laser Doppler
perfusion imaging was performed at the indicated days after
surgery. There were no significant differences among treat-
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Figure 1. UnAG protects against ischemia-mediated functional impairment in skeletal muscle. A, Histogram representation of limb perfusion
reported as ratio (meanSEM, n=27 for each group) of ischemic to normal hindlimb for each group of mice (0b: before surgery; 0a: after surgery;
***P<0.001 ischemic limb vs normal limb). B, Foot damage score was evaluated for the indicated times as reported in Methods. Data are
expressed as meanSEM, n=27 (***P<0.001 ischemic limb of UnAG mice vs ischemic limb of AG and saline mice). C, The graph represents the
number of vessels in ischemic (ih) and normo-perfused (nh) gastrocnemius muscles of each group of animals, evaluated by 3 different operators
counting 10 fields at 940 magnification and are reported as meanSEM (n=9 each group at day 7 and at day 21) of vessels per field
(***P<0.001 ih muscles of UnAG mice vs ih muscles of AG and saline mice at days 7 and 21). D, Representative hematoxylin and eosin–stained
sections of ischemic and normo-perfused (normal) muscles from UnAG-, AG-, and saline-treated mice, at days 7 and 21 post surgery. Scale bar:
80 lm (920 magnification). Insets show myofibers at higher magnification; green arrows indicate regenerating myofibers, characterized by
central nucleus location at days 7 and 21 in UnAG mice. E, Quantification of the percentage (meanSEM) of regenerating fibers, characterized by
the presence of centrally located nucleus. UnAG-, AG-, and saline-treated mice were analyzed at days 7 and 21 postsurgery (***P<0.001 ischemic
muscles of UnAG-treated mice vs AG- and saline-treated mice at days 7 and 21; normal muscles vs ischemic muscles of treated mice).
F, Quantification of inflammatory cells in the ischemic and normal muscles of UnAG-, AG-, and saline-treated mice, at days 7 and 21 postsurgery.
Data are expressed as meanSEM of CD68+ cells per field (940 magnification) (***P<0.001 ischemic muscles of AG- and saline- vs UnAG-
treated mice at days 7 and 21; normal muscles vs ischemic muscles of treated mice). E and F: n=9 each group at day 7 and at day 21. AG
indicates acylated ghrelin; UnAG, unacylated ghrelin.
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ment groups in large-vessel reperfusion (Figure 1A). However,
when a functional score was applied, the damage was
significantly higher in saline- and AG-treated groups than in
the UnAG-treated group even at days 1, 3, and 5 (Figures 1B
and 2A). Similar results were obtained in Balb/c mice (data
not shown).
To assess whether these functional differences were due
to differences in tissue reperfusion, the number of vessels
was counted in ischemic muscles of treated animals at
different intervals. UnAG-treated mice had a larger number of
functional vessels compared with the other groups (Figures
1C and 3). Furthermore, ischemic muscles from AG- and
saline-treated mice had a significantly lower capillary density
than in contralateral control muscles from the same animals,
whereas no such differences were observed in UnAG-treated
animals (Figure 1C). This effect was already evident at day 3
and 5 (data not shown). Analysis of tissue regeneration in
gastrocnemius muscles revealed that muscles from UnAG-
treated mice contained an increased number of regenerating
myofibers starting from day 7 (Figures 1D, 1E, and 2B). In
addition, those mice had a reduced number of CD68+
inflammatory cells throughout the treatment (Figures 1F and
4). No changes were observed in the numbers of regenerating
fibers or CD68+ inflammatory cells in normo-perfused mus-
cles (Figure 1D through 1F). Thus, in our model, UnAG but not
AG appears to protect against ischemia-induced damage.
Figure 2. Effects of UnAG and AG at days 1, 3, and 5 after ischemia. A, Foot damage score of treated mice was evaluated for the indicated
times. Data are expressed as meanSEM (n=3 each group at days 1, 3, and 5) (***P<0.001 ischemic limb of UnAG- vs AG- and saline-treated
mice). B, Representative hematoxylin and eosin–stained sections of ischemic muscles from UnAG-, AG-, and saline-treated mice at days 1, 3, and
5 post surgery. Scale bar: 80 lm (920 magnification). Black arrows indicate the inflammatory infiltrates. C, Sections of ischemic muscles
recovered from treated mice at days 3 and 5 post surgery and stained for Pax-7 (green), MyoD (red), and DAPI (blue). Yellow arrows indicate Pax-
7+/MyoD+ cells. Scale bar: 40 lm (940 magnification). Quantification of Pax-7+/MyoD+ cells per field (940 magnification) in ischemic limb of
treated mice is reported (meanSEM (n=3 each group at days 3 and 5) (***P<0.001 Pax-7+/MyoD+ cells in UnAG- vs AG- and saline-treated mice
at day 5). AG indicates acylated ghrelin; UnAG, unacylated ghrelin.
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UnAG Increases the Number of Pax-7/MyoD–
Positive Cells
Skeletal muscle regeneration in vivo depends on the expan-
sion and differentiation of SCs9 coexpressing Pax-7 and
MyoD. Thus, the number of cells expressing both Pax-7 and
MyoD was evaluated at different intervals. Small numbers of
double-positive cells were already detectable at day 5 in
UnAG mice (Figure 2C). This effect was much more evident at
day 7. In fact, at day 7 ischemic muscles from UnAG-treated
mice had an increased number of Pax-7+/MyoD+ cells
compared with ischemic muscles from AG-treated and control
mice (Figure 5A and 5B). At day 21, scattered Pax-7+/MyoD+
cells were still present in ischemic muscles from UnAG- but
not AG- or saline-treated mice (Figures 5A, 5B, and 6). To
evaluate in vivo data, SCs were isolated and counted (Figure
5C). This ex vivo evaluation revealed a significantly increased
number of Pax-7+/MyoD+ SCs in UnAG-treated mice com-
pared with AG- and saline-treated animals (Figure 5C through
Figure 3. Vessel quantification. Sections of ischemic muscles
recovered from saline-, AG-, and UnAG-treated mice at days 7 and
21 post surgery and stained for CD31 (green) and DAPI (blue). White
arrows indicate vessels. Scale bar: 40 lm (940 magnification). The
graph represents the number of vessels in ischemic muscles of each
group of animals, evaluated by 3 different operators counting 10
fields at 940 magnification, and reported as meanSEM (n=9 each
group at day 7 and at day 21) of vessels per field (***P<0.001
ischemic muscles of UnAG- vs AG- and saline-treated mice at days 7
and 21). AG indicates acylated ghrelin; UnAG, unacylated ghrelin.
Figure 4. Inflammatory cell infiltration. Sections of ischemic mus-
cles recovered from saline-, AG-, and UnAG-treated mice at days 7
and 21 post surgery and stained for CD68 (red) and DAPI (blue).
Scale bar: 40 lm (940 magnification). Quantification of inflamma-
tory cells in the ischemic muscles from UnAG-, AG-, and saline-
treated mice, at days 7 and 21 post surgery. Data are expressed as
meanSEM (n=9 each group at day 7 and at day 21) of CD68+ cells
per field (940 magnification) (***P<0.001 ischemic muscles of AG-
and saline- vs UnAG-treated mice at days 7 and 21). AG indicates
acylated ghrelin; UnAG, unacylated ghrelin.
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Figure 5. UnAG activates the myogenic process. A, Representative sections of ischemic muscles recovered from saline-, AG-, and UnAG-treated
mice stained for Pax-7 (green), MyoD (red), and DAPI (blue). Yellow arrows indicate Pax7+/MyoD+ cells. Scale bar: 40 lm (940 magnification). B,
Quantification of Pax-7+/MyoD+ cells in ischemic muscles at day 7. Data are expressed as meanSEM of Pax-7+/MyoD+ cells per field (940
magnification) (***P<0.001 ischemic muscles from UnAG- vs AG- and saline-treated mice at day 7). C, Number (meanSEM) of Pax-7+/MyoD+
SCs recovered from ischemic muscles of treated mice, at days 7 and 21 post surgery (*P<0.05 SCs from UnAG- vs AG- and saline-treated mice at
day 21; ***P<0.001 SCs from UnAG- vs AG- and saline-treated mice at day 7; ***P<0.001 SCs from treated mice at day 7 vs day 21). D and E,
Cell extracts from SCs recovered from ischemic muscles at day 7 were analyzed by Western blot for Pax-3, Pax-7, and phospho(p)-p38/MAPK (D)
or for Myf5 and MyoD content (E). Protein levels were normalized to tubulin or p38/MAPK content (**P<0.01 Pax-3 content in ischemic SCs from
UnAG- vs AG- and saline-treated mice; ***P<0.001 Pax-7 and p-p38/MAPK content in ischemic SCs from UnAG- vs AG- and saline-treated mice;
***P<0.001 Myf5 and Myo-D content in ischemic SCs from UnAG- vs AG- and saline-treated mice). F, Sections of ischemic muscles stained for
MyoD (red), myogenin (green), and DAPI (blue) recovered from treated mice at days 7 and 21 post surgery. Red arrows indicate MyoD+ cells,
green arrows indicate myogenin+ cells, and yellow arrow indicates MyoD+/myogenin+ cells. Scale bar: 40 lm (940 magnification). Quantification
of myogenin+ cells per field (940 magnification) in ischemic limb of treated mice is reported (meanSEM) (*P<0.05 myogenin+ cells in UnAG- vs
AG- and saline-treated mice at day 7; ***P<0.001 myogenin+ cells in UnAG- vs AG- and saline-treated mice at day 21). G, Pax-7 and myogenin
content was evaluated by Western blot in SCs from ischemic muscles of treated animals (day 21). Protein level was normalized to tubulin content
(***P<0.001 myogenin content in SCs from ischemic muscles of UnAG- vs AG- and saline-treated mice). Results are representative of all
experiments. A, B, C, and F, n=9 each group at days 7 and 21; D and E, n=9 each group at day 7; G, n=9 each group at day 21. AG indicates
acylated ghrelin; SC, satellite cell; MAPK, mitogen-activated protein kinase; UnAG, unacylated ghrelin.
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5E) at day 7. Besides Pax-7, Pax-342,43 was expressed in SCs
recovered from UnAG- but not AG- or saline- treated mice
(Figure 5D). Consistent with previous reports indicating that
SC proliferation depends on p38/MAPK activation,8,9 levels
of phospho(p)-p38/MAPK protein at day 7 were found to be
higher in SCs from UnAG-treated mice than in those from
saline- or AG-treated groups (Figure 5D). Myf5 was also
expressed at day 7 in SCs from UnAG mice. In addition, the
presence of a few MyoD+/myogenin+ cells was detectable in
ischemic muscles from UnAG-treated mice at day 7 (Figure
5F). Double-positive cells were almost undetectable at day
21. At day 21, the majority of cells were MyoD/myogenin+
(Figure 5F and 5G). Scattered Pax-7+/MyoDcells were
detected in normo-perfused muscles in all groups (data not
shown).
UnAG Induces SOD-2 Expression in SCs
Subjected to Ischemia
Increased ROS production and decreased antioxidant
response seem to be crucial determinants of tissue damage
in ischemic conditions.5 Thus, TBARS were first evaluated in
ischemic muscles. Significant increases in the concentration
of TBARS were observed in AG- and saline- but not UnAG-
treated muscles (Figure 7A). These data suggest that UnAG
may exert its biological effects by inducing an efficient
antioxidant response. Since the mitochondria-specific antiox-
idant enzyme SOD-2 is known to be diminished in patients
with PAD,5 we analyzed SOD-2 expression and ROS content in
SCs isolated from different groups. We found that ROS
production was lower and SOD-2 protein expression higher in
SCs from UnAG-treated mice than in SCs from AG- or saline-
treated animals (Figure 7B and 7C). Furthermore, double
immunostaining of ischemic muscles from UnAG-treated mice
revealed an increased number of SOD-2+/Pax-7+ cells
compared with AG-treated mice and controls (Figure 7D).
To validate the possibility that UnAG acts by inducing an
efficient antioxidant response, UnAG was administered to
mice treated with BaCl2, which is known to induce ROS-
independent damage.44 As shown in Figure 8, regeneration of
skeletal muscle was no longer observed. Thus, UnAG appears
to influence skeletal muscle regeneration via an antioxidant
effect.
UnAG-Induced SC Cell-Cycle Entry Is
Recapitulated In Vitro
To evaluate whether the in vivo effects of UnAG are
recapitulated in vitro, primary SCs recovered from normo-
perfused muscles were subjected to in vitro ischemia and
evaluated on treatment. Again, only UnAG challenge induced
expression of Pax-7, MyoD (Figure 9A), and myogenin (Figure
9B) and increased levels of p-p38/MAPK (Figure 9C). In
addition, UnAG challenge increased PCNA expression (Figure
9D) and the number of cells in the S phase (Figure 9E).
When examined under the same experimental conditions,
ROS production was decreased (Figure 9F) and SOD-2 expres-
sion increased (Figure 9G) following UnAG treatment. When
Figure 6. Pax-7 and MyoD co-localization at day 21 after ischemia. Sections of ischemic muscle recovered from saline-, AG-, and UnAG-treated
mice at day 21 post surgery and stained for Pax-7 (green), MyoD (red), and DAPI (blue). Yellow arrows indicate merged Pax7+/MyoD+ cells. Scale
bar: 40 lm (940 magnification). Quantification of Pax7+/MyoD+cells in ischemic muscles of treated animals at day 21 is reported. Data are
expressed as meanSEM (n=9 each group at day 7 and at day 21) of Pax7+/MyoD+ cells per field (940 magnification) (***P<0.001 ischemic
muscles of UnAG- vs AG- and saline-treated mice at day 21). AG indicates acylated ghrelin; UnAG, unacylated ghrelin.
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SOD-2 was silenced in SCs using siRNA (Figure 10A) and SCs
subjected to in vitro ischemia, UnAG did not protect SCs against
ROS generation (Figure 10B) and did not induce p38/MAPK
phosphorylation (Figure 10D), and the cells did not undergo cell-
cycle progression (Figure 10C). Moreover, the addition of
SB202190, an inhibitor of p38/MAPK phosphorylation,
blocked cell-cycle entry and prevented MyoD and myogenin
expression in SCs exposed toUnAG (Figure 10E and10F). These
data indicate that, after ischemia, SOD-2 expression is crucial
for UnAG-induced p38/MAPK phosphorylation, leading to
activation of the myogenic process. Finally, the specificity of
UnAG activity in SCs subjected to ischemia is supported by the
finding that the retro-des-acyl ghrelin peptide (1–14)32 was
unable to induce similar effects and UnAG had no effect on
SOD-2 expression in non-SCs (Figure 11A and 11B).
UnAG-Mediated SC Proliferation s Independent of
Akt or Hepatocyte Growth Factor
It has been reported that both AG and UnAG activate PI3Kb-
mTORC2 pathways in C2C12 cell line and protect myotubes
from dexamethazone-induced atrophy.27 In our in vitro model
Figure 7. UnAG prevents ROS production in SCs by inducing SOD-2 expression. A, TBARS were determined in gastrocnemius muscle of UnAG-,
AG-, and saline-treated mice at days 7 and 21 after ischemia. Values are expressed as nanomoles per gram of dry tissue (meanSEM, n= 6 each
group at days 7 and 21) (***P<0.001 ischemic muscle of UnAG-treated mice vs AG- and saline-treated mice at day 7; *P<0.05 ischemic muscle
of UnAG-treated mice vs AG- and saline-treated mice at day 21). B, To evaluate ROS generation, DCF-DA assay was performed on SCs recovered
from muscles of UnAG-, AG-, and saline-treated mice at day 7 after ischemia. The percentage of DCF-DA+ cells (meanSEM, n=6 each group) is
reported (***P<0.001 ROS generation in ischemic muscles from UnAG- vs AG- and saline-treated mice). C, SCs recovered from ischemic muscles
of treated mice were subjected to Western blot normalized to a-actin content; SOD-2 content was evaluated. The results are representative of all
experiments (n=6 each group) (***P<0.001 ischemic SCs from UnAG- vs AG- and saline-treated mice). D, Representative stained sections for
Pax-7 (red), SOD-2 (green), and DAPI (blue) of muscles recovered at day 7 after ischemia. Yellow arrows indicate Pax7+/SOD-2+ cells. Scale bar:
40 lm (940 magnification). Quantification of Pax-7+/SOD-2+ cells per field (940 magnification) in ischemic muscles of treated mice is reported
in the histogram (meanSEM, n=9 each group) (***P<0.001 UnAG treatment vs AG and saline treatment at day 7). AG indicates acylated ghrelin;
DCF-DA, 5- (and 6-)carboxy-2′,7′-dichlorofluorescein diacetate; ROS, reactive oxygen species; SC, satellite cell; SOD-2, superoxide dismutase-2;
UnAG, unacylated ghrelin; TBARS, thiobarbituric acid reactive substances.
Figure 8. UnAG has no protective effect against toxic damage.
Representative hematoxylin and eosin–stained sections of toxic
damage induced by injection of 1% barium chloride (BaCl2) in
gastrocnemius muscles of C57BL/6J mice. Mice were treated as
indicated, n=3 each group. AG indicates acylated ghrelin; UnAG,
unacylated ghrelin.
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of ischemia, we were unable to demonstrate the activation of
these signaling pathways (data not shown). Similarly, treat-
ment with the specific Akt inhibitor TCL110-24 showed that
protection against ROS generation was independent of Akt in
C2C12 cell line (Figure 12). Moreover, Akt inactivation had no
significant effects on p38/MAPK activation and SOD-2, Pax-7,
or myogenin expression in either C2C12 cells (Figure 12A) or
SCs (data not shown).
Figure 9. UnAG effects are recapitulated in vitro in primary SCs. A through C, SCs recovered from normoperfused muscles were treated for
72 hours with the indicated stimuli and subjected to in vitro ischemia for an additional 24 hours. Cell extracts were analyzed by Western blot
for Pax-7 and MyoD (A), for myogenin (B), and for p-p38/MAPK content (C) by densitometry (relative amount). Protein levels were normalized
to tubulin or p38/MAPK content. The results are representative of 5 different experiments performed in triplicate (n=5) (***P<0.001 Pax-7
and MyoD [A], myogenin [B], and p-p38/MAPK [C] content in UnAG- vs AG- or saline-treated SCs). D, SCs subjected to in vitro ischemia and
treated as indicated were analyzed by FACS for PCNA expression. The graph is representative of 5 independent experiments. E, FACS analysis
indicates the percentage of SCs, treated as above, in the different cell-cycle phases. The results are representative of 5 different experiments
performed in triplicate. F, To evaluate ROS generation, DCF-DA assay was performed on SCs subjected to in vitro ischemia and treated as
indicated. The percentage of DCF-DA+ cells (meanSEM, n=5) is reported (***P<0.001 ROS generation in UnAG- vs AG- and saline-treated
SCs). G, SOD-2 content was analyzed by Western blot (normalized to a-actin) in SCs subjected to in vitro ischemia. The results are
representative of 5 different experiments performed in triplicate (**P<0.01 UnAG- vs AG- and saline-treated SCs). AG indicates acylated
ghrelin; DCF-DA, 5- (and 6-)carboxy-2′,7′-dichlorofluorescein diacetate; MAPK, mitogen-activated protein kinase; ROS, reactive oxygen species;
SC, satellite cell; SOD-2, superoxide dismutase-2; UnAG, unacylated ghrelin; FACS, fluorescence-activated cell sorting; PCNA, proliferating cell
nuclear antigen.
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It has been extensively reported that after muscle injury,
SCs activate cell-cycle entry in an hepatocyte growth factor–
dependent manner.45–47 Therefore, we investigated the
contribution of hepatocyte growth factor in mediating UnAG
action. To this end, SCs treated with UnAG or saline were
subjected to in vitro ischemia in the presence or absence of
Figure 10. UnAG induces SC cell-cycle entry via SOD-2 and p38/
MAPK phosphorylation. A, SCs recovered from normo-perfused
muscles were treated for 72 hours with the indicated stimuli and
subjected to in vitro ischemia. SOD-2 content was evaluated in SCs
transfected for the last 48 hours with scramble or SOD-2 siRNA.
Protein level was normalized to a-actin. The results are representa-
tive of 4 different experiments performed in triplicate (***P<0.001
SCs transfected with the SOD-2 siRNA vs SCs transfected with the
scramble). B, To evaluate ROS generation, DCF-DA assay was
performed on SCs depleted for SOD-2 and treated as indicated (n=4).
C, FACS analysis indicates the percentage of SCs transfected with
scramble or with SOD-2 siRNA in the presence of UnAG in the
different cell-cycle phases. The results are representative of 4
different experiments performed in triplicate. D, SCs transfected with
scramble or SOD-2 siRNA and subjected to in vitro ischemia in the
presence of UnAG were analyzed by Western blot for p-p38/MAPK
content by densitometry (relative amount). The results are represen-
tative of 4 different experiments performed in triplicate (**P<0.01
SOD-2–silenced SCs vs scramble-transfected SCs). E, FACS analysis
indicates the percentage of SCs in the different cell-cycle phases
following treatment with the indicated stimuli. The results are
representative of 4 different experiments performed in triplicate. F,
Cell extracts from SCs treated as indicated were analyzed by Western
blot for MyoD and myogenin content by densitometry (relative
amount). Protein levels were normalized to tubulin content. The
results are representative of 4 different experiments performed in
triplicate. AG indicates acylated ghrelin; DCF-DA, 5-(and 6-)carboxy-
2′,7′-dichlorofluorescein diacetate; ROS, reactive oxygen species; SC,
satellite cell; siRNA, small interfering RNA; MAPK, mitogen-activated
protein kinase; SOD-2, superoxide dismutase-2; UnAG, unacylated
ghrelin; FACS, fluorescence-activated cell sorting.
Figure 11. A, Scramble peptide vs UnAG treatment. SCs recovered
from normo-perfused muscles and subjected to in vitro ischemia were
treated with scramble peptide or UnAG. Cell extracts were analyzed
by Western blot for p-p38/MAPK and SOD-2 (left) and for Pax-7 and
MyoD (right) content by densitometry (relative amount). Protein levels
were normalized to p38/MAPK, a-actin, or tubulin content. The
results are representative of 5 different experiments performed in
triplicate (***P<0.001 p-p38/MAPK and SOD-2 content in UnAG-
treated SCs vs scramble-treated SCs; ***P<0.001 Pax-7 and MyoD
content in UnAG-treated SCs vs scramble-treated SCs). B, SOD-2
content in UnAG-treated non-SCs. Cell extracts from COS-7 cells,
treated as indicated and subjected or not to in vitro ischemia, were
analyzed by Western blot for SOD-2 content by densitometry (relative
amount). Protein levels were normalized to a-actin content. The
results are representative of 5 different experiments performed in
triplicate. AG indicates acylated ghrelin; SC, satellite cell; SOD-2,
superoxide dismutase-2; UnAG, unacylated ghrelin.
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the c-Met kinase inhibitor Crizotinib.48 The results reported in
Figure 13 demonstrate that the c-Met kinase inhibitor did not
interfere with UnAG.
UnAG Acts Independently of Ghrelin to Induce
Skeletal Muscle Regeneration
To assess whether the effects of UnAG on SC fate occurred
through the classic ghrelin signaling pathway, we analyzedmice
lacking the GHSR1a and ghrelin genes.36 SCs from these
double-knockoutmice were subjected to in vitro ischemia in the
presence of AG or UnAG. Again, only UnAG promoted SC cell-
cycle progression (Figure 14A) and induced p-p38/MAPK,
Pax-7, MyoD, Myf5, and myogenin expression (Figure 14B and
14C). Moreover, unlike AG, UnAG protected SCs from ROS
generation and induced SOD-2 expression (Figure 14C and
14D). We cannot exclude the possibility that, similar to C2C12
cells,25,27 SCs express a receptor shared by AG and UnAG.
However, these results, along with the failure to detect in vivo
effects of AG, support the possibility that UnAG can induce AG-
independent activities in SCs. Along with data obtained in
endothelial progenitor cells31 and neonatal cardiomiocytes,30
our findings thus suggest the existence of an additional
unidentified receptor for UnAG.
Figure 12. Akt is not involved in UnAG-mediated signals in C2C12 cells subjected to in vitro ischemia. A, Cell extracts from C2C12 cells, treated
as indicated and subjected to in vitro ischemia, were analyzed by Western blot for pAkt, SOD-2, p-p38/MAPK, Pax-7, and myogenin content by
densitometry (relative amount). Protein levels were normalized to Akt, a-actin, p38/MAPK, or tubulin content. The results are representative of 5
different experiments performed in triplicate (*P<0.05 myogenin content in UnAG-treated cells+iAkt vs AG- and saline-treated cells+iAkt;
**P<0.01 SOD-2 content UnAG-treated cells+iAkt vs saline-treated cells+iAkt; myogenin content in UnAG- vs AG- and saline-treated cells;
***P<0.001 SOD-2, p-p38/MAPK, and Pax-7 content in UnAG- vs AG- and saline-treated cells; ***P<0.001 p-p38/MAPK and Pax-7 content in
UnAG-treated cells+iAkt vs saline-treated cells+iAkt). B and C, To evaluate ROS generation, DCF-DA assay was performed on C2C12 cells
subjected to in vitro ischemia and treated as indicated in the presence or absence of Akt inhibitor. The percentage of DCF-DA+ cells (meanSEM,
n=5) is reported (***P<0.001 ROS generation in UnAG- vs AG- and saline-treated cells in the presence or absence of Akt inhibitor). AG indicates
acylated ghrelin; DCF-DA, 5- (and 6-)carboxy-2′,7′-dichlorofluorescein diacetate; ROS, reactive oxygen species; SOD-2, superoxide dismutase-2;
UnAG, unacylated ghrelin.
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miR-221 and miR-222 Control UnAG-Induced
SC Cell-Cycle Entry by Regulating the Expression
of p57 Kip2 but Not That of p27 Kip1
To address the molecular mechanism through which UnAG
exerts its effects, we analyzed the expression of miR-221
and miR-222, which have recently emerged as important
regulators of myogenesis.13,14 Expression of miR-221 and
miR-222 was significantly increased in SCs recovered from
muscles of UnAG-treated mice compared with controls
(Figure 15A). We therefore analyzed the expression of
p27Kip1 and p57Kip2, known target genes of miR-221/
222,13,49 and found that only the levels of p57Kip2 protein
were reduced in SCs from UnAG-treated mice (Figure 15B).
Similar results were obtained when SCs recovered from
normo-perfused muscles were subjected to in vitro ischemia
and treated with UnAG (Figure 15C and 15D). To ascertain
the direct effect of miR-221/222 on p57Kip2-3’-UTR, a
luciferase reporter vector containing the wild-type full-length
p57Kip2-3′-UTR was transfected in SCs. Decreased luciferase
activity was detected in p57Kip2-3′-UTR expressing SCs
exposed to in vitro ischemia (Figure 15E). Furthermore, in
loss-of-function experiments involving transfection of SCs
with anti–miR-221/222 (Figure 16), UnAG no longer had
any effect on cell-cycle entry or expression of Pax-7, MyoD,
or myogenin in SCs (Figure 15F and 15G). The observation
that p-p38/MAPK levels were reduced under these exper-
imental conditions (Figure 15G) provides further evidence
Figure 13. The c-Met kinase inhibitor does not affect UnAG-mediated signals in SCs subjected to in vitro ischemia. A, Cell extracts from SCs,
treated with saline and UnAG in the presence or absence of c-Met kinase inhibitor and subjected to in vitro ischemia, were analyzed by Western
blot for phospho-c-Met (pMet), p-p38/MAPK, SOD-2, and Pax-7 content by densitometry (relative amount). Protein levels were normalized to
c-Met, p38/MAPK, a-actin, or tubulin content. The results are representative of 5 different experiments performed in triplicate (*P<0.05 p-p38/
MAPK and SOD-2 content in UnAG- vs saline-treated cells; pMet content in saline- and UnAG-treated cells+iMet vs saline- and UnAG-treated cells;
SOD-2 content in UnAG-treated cells+iMet vs saline-treated cells+iMet **P<0.01 Pax-7 content in UnAG- vs saline-treated cells; p-p38/MAPK
and Pax-7content in UnAG-treated cells+iMet vs saline-treated cells+iMet). B and C, To evaluate ROS generation, DCF-DA assay was performed on
SCs subjected to in vitro ischemia and treated as indicated in the presence or absence of c-Met kinase inhibitor. The percentage of DCF-DA+ cells
(meanSEM, n=5) is reported (***P<0.001 ROS generation in UnAG- vs AG- and saline-treated cells in the presence or absence of c-Met kinase
inhibitor). AG indicates acylated ghrelin; DCF-DA, 5- (and 6-)carboxy-2′,7′-dichlorofluorescein diacetate; ROS, reactive oxygen species; SC, satellite
cell; SOD-2, superoxide dismutase-2; UnAG, unacylated ghrelin.
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that both miRs are crucial mediators of myogenesis.
Interestingly, loss-of-function experiments demonstrate that
miR-221/222 are under the control of SOD-2 expression
(Figure 15G).
miR-221/222 Expression Is Modulated by
Oxidative Stress and Is Crucial for Skeletal
Muscle Regeneration on Ischemia
To validate the relevance of SOD-2 in miR-221/222 expres-
sion, the in vitro ischemia was induced following SOD-2
depletion (Figure 17A). Under these conditions, UnAG-induced
miR-221/222 expression was blocked (Figure 17B), suggest-
ing that miR-221/222 expression could be modulated by ROS
generation. It would therefore be expected that miR-221/222
overexpression protects against ischemia-induced damage. To
assess this possibility, we analyzed the in vivo role of miR-
221/222 in skeletal muscle regeneration by injection of pre–
miR-221/222 in our model. Under these conditions, pre–miR-
221/222 injection led to lower damage scores and significant
myofiber regeneration (Figure 17C through 17E) even in the
absence of UnAG. Furthermore, SCs recovered from those
mice had high levels of miR-221/222 expression (Figure 17F)
and increased levels of MyoD, myogenin, and p-p38/MAPK
protein (Figure 17G).
Discussion
In this study, we have shown that UnAG improves skeletal
muscle regeneration in a mouse model of CLI by inducing
protective effects against ROS-induced cell injury. In partic-
ular, we found that ROS imbalance is corrected by UnAG-
mediated SOD-2 expression in SCs. This expression of SOD-2
is also crucial for SC cell-cycle entry via a mechanism
involving miR-221/222. Taken together, these data suggest
that UnAG treatment could offer clinical benefit in the
treatment of PAD and provide important insights into its
mechanism of action.
A major factor in the development of symptoms and
skeletal muscle damage in PAD is the persistence of an
oxidative environment.5 In our study, although there was no
effect of AG or UnAG treatment on large-vessel reperfusion,
ischemic muscles of UnAG-treated mice had a larger number
of functional vessels than observed in AG- or saline-treated
animals. Furthermore, the number of vessels was similar in
ischemic and normo-perfused muscles from UnAG-treated
Figure 14. UnAG induces cell-cycle entry of SCs from double-KO mice via SOD-2 and p38/MAPK phosphorylation. A, SCs recovered from
double-KO mice were stimulated with saline, AG, and UnAG and subjected to in vitro ischemia. FACS analysis was performed to evaluate SC cell-
cycle progression. The results are representative of 5 different experiments performed in triplicate. B and C, Cell extracts from KO-derived SCs,
treated as indicated and subjected to in vitro ischemia, were analyzed by Western blot for Pax-7, MyoD, Myf5, and myogenin (B) and for p-p38/
MAPK and SOD-2 (C) content by densitometry (relative amount). Protein levels were normalized to tubulin, p38/MAPK, or a-actin content. The
results are representative of 5 different experiments performed in triplicate (***P<0.001 Pax-7, MyoD, Myf5, and myogenin content in SCs
derived from UnAG- vs AG- and saline-treated double-KO mice; ***P<0.001 p-p38/MAPK and SOD-2 in SCs derived from UnAG- vs AG- and
saline-treated double-KO mice). D, To evaluate ROS generation, DCF-DA assay was performed on SCs derived from double-KO mice, treated as
indicated. The percentage of DCF-DA+ cells (meanSEM, n=5) is reported (*P<0.05 ROS generation in UnAG- vs AG- and saline-treated SCs). AG
indicates acylated ghrelin; DCF-DA, 5- (and 6-)carboxy-2′,7′-dichlorofluorescein diacetate; KO, knockout; ROS, reactive oxygen species; SC,
satellite cell; SOD-2, superoxide dismutase-2; UnAG, unacylated ghrelin.
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Figure 15. UnAG induces SC cell-cycle entry by regulating miR-221/222 expression. A, miR-221/222 expression was evaluated by qRT-PCR on
SCs from ischemic (ih) and nonischemic (nh) muscles of mice treated as indicated, at days 7 and 21 post surgery. Data normalized to RNU6B are
representative of 9 experiments (n=9 each group) (miR-221/222 expression: ***P<0.001 ih SCs from UnAG- vs saline-treated mice at day 7;
**P<0.01 ih SCs from UnAG- vs saline-treated mice for miR-221 and ***P<0.001 ih SCs from UnAG- vs saline-treated mice for miR-222 at day 21
[s indicates saline; U, UnAG]). B, p57kip2 and p27kip1 content was analyzed in SCs from ih and nh muscles at days 7 and 21 by densitometry
(relative amount) (n=9 each group at days 7 and 21: **P<0.01 p57kip2 in SCs from ischemic muscle of UnAG-treated mice vs the other
experimental groups at day 7; *P<0.05 p57kip2 in ih SCs from UnAG- vs saline-treated mice at day 21). C, miR-221/222 expression was analyzed
by qRT-PCR on SCs from nh muscles subjected to in vitro ischemia and treated as indicated. Data normalized to RNU6B are representative of 5
different experiments performed in triplicate (***P<0.001 UnAG- vs saline-treated SCs). D, Cell extracts from SCs treated as above were analyzed
for p57kip2 and p27kip1 content and normalized to a-actin content. The results are representative of 5 different experiments performed in triplicate
(***P<0.001 p57kip2 in UnAG- vs saline-treated SCs). E, SCs were transfected with pmiR empty vector or pmiR-3′-UTR p57kip2 luciferase
constructs, treated as indicated and subjected to in vitro ischemia. The relative luciferase expression is reported (***P<0.001 UnAG- vs saline-
treated SCs) (n=3). F, SCs, transfected with anti-miR negative control (neg c) or anti–miR-221/222 were subjected to in vitro ischemia. SC cell-
cycle progression was analyzed by FACS. Results are representative of 5 different experiments performed in triplicate. G, MyoD, Pax-7, myogenin,
p-p38/MAPK, and SOD-2 content was analyzed on SCs stimulated as above. Protein levels were normalized to tubulin, p38/MAPK, or a-actin
content. Results are representative of 5 different experiments performed in triplicate (***P<0.001 Pax-7, MyoD, myogenin, and p-p38/MAPK
in UnAG-treated SCs+anti-miR neg c vs saline-treated SCs+anti-miR neg c; ***P<0.001 SOD-2 in UnAG-treated SCs+anti-miR neg c and
UnAG-treated SCs+anti–miR-221/222 vs saline treatment; ***P<0.001 MyoD, Pax-7, myogenin, and p-p38/MAPK content in UnAG-treated
SCs+anti–miR-221/222 vs UnAG-treated SCs+anti-miR neg c). qRT-PCR indicates quantitative real-time PCR; miR, microRNA; SC, satellite cell;
SOD-2, superoxide dismutase-2; UnAG, unacylated ghrelin; FACS, fluorescence-activated cell sorting.
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mice. Since UnAG protects endothelial cells and endothelial
progenitor cells against apoptosis and senescence without
promoting proliferation,26,31 these data suggest that UnAG
protects muscles against ischemia-induced tissue injury
rather than promoting neovessel formation. This possibility
is further supported by our observation of a low number of
proangiogenic infiltrating CD68+ cells50 and a low score for
hindlimb functional damage in UnAG-treated animals.
One possibility to explain the reduction of ischemia-
induced injury by UnAG treatment is via an effect on skeletal
muscle regeneration. We found that UnAG promotes skeletal
muscle regeneration by inducing cell-cycle entry and gener-
ation of Pax-7+/MyoD+ myoblasts by SCs. Recently, it has
been reported that asymmetric activation and localization of
p38/MAPK in dividing cells dictate myoblast expansion.9
Consistent with that observation, we found that p38/MAPK
was phosphorylated in SCs recovered from ischemic muscles
of UnAG-treated mice. Moreover, SCs subjected to in vitro
ischemia and exposed to UnAG undergo cell-cycle progres-
sion by p38/MAPK phosphorylation.
Our finding that UnAG treatment on ischemia leads to the
generation of myogenin-positive cells and regenerating myof-
ibers suggests that, directly or indirectly, UnAG-mediated
signals might play a role in driving the myogenic differenti-
ating program. The SC population is considered heteroge-
neous in terms of gene expression, myogenic differentiation
potential, and propensity to generate stem cells.47,51 Pax-7 is
widely expressed, whereas expression of its paralog Pax-
342,43 is less widespread and does not correlate with the
embryonic origin or innervation of SCs.52 We found that UnAG
treatment on ischemia led to expansion of a population of SCs
that express Pax-7 and Pax-3 as well as Myf5 and MyoD,
which are specific markers of differentiating myoblasts.47 It is
well established that, after limited round of proliferation,
terminal differentiation starts with the expression of myoge-
nin,53,54 primarily induced by the transcriptional activity of
MyoD.55 Thus, the presence of myogenin-positive cells and
regenerating myofibers in our model is consistent with the
promotion of muscle regeneration by UnAG. Recently, Porp-
orato et al27 demonstrated that transgenic mice constitutively
producing high levels of UnAG exhibit long-term protection
against experimentally induced muscle atrophy. Furthermore,
it is well established that long-term denervation causes a
severe reduction of SC numbers and thus leads to muscle
atrophy.47,56 Thus, as the reduced number of SCs is, at least
in part, due to the impaired capability of SCs to enter the cell
cycle,57 it is conceivable that the protective effect observed in
the transgenic mice could depend on UnAG-mediated func-
tional recovery of SCs.
Consistent with our previous finding that UnAG, unlike AG,
acts by reducing ROS production,31,32 we found that the
formation of TBARS was significantly lower in muscles
recovered from UnAG-treated mice than in those from AG-
treated mice. In addition, SCs recovered from ischemic
muscles of UnAG-treated animals displayed a low intracellular
ROS content. Importantly, mice subjected to ROS-indepen-
dent damage did not benefit of UnAG administration. Thus,
our data suggest that the effect of UnAG on skeletal muscle
regeneration mainly occurs via a mechanism involving
protection of SCs against oxidative damage.
The primary enzymatic antioxidant defense against intra-
cellular ROS relies on efficient antioxidant machinery,5
including SOD-2. Not surprisingly, SOD-2 is diminished in
muscles of patients with PAD and this seems to contribute to
tissue damage.5 Given that, under ischemic conditions, UnAG
prevents ROS generation, we investigated its effects on SOD-
2 expression. We found that SOD-2 could be detected in Pax-
7+ cells and its expression was increased in SCs from UnAG-
but not AG- or saline-treated animals. Thus, the promotion of
SC cell-cycle entry and skeletal muscle regeneration by UnAG
appears to occur via an antioxidant effect promoted by the
upregulation of SOD-2 expression. Together, these data
suggest that UnAG recapitulates the defense against ROS
observed in p66Shc-A knockout mice19 and that aging-related
diseases16,17 and myotonic dystrophy type 1,58 characterized
by mitochondrial dysfunction and increased ROS generation,
might also benefit from UnAG treatment.
Figure 16. In vitro loss-of-function experiments. Following trans-
fection with anti-miR neg ctrl or anti–miR-221/222, qRT-PCR was
performed on SCs treated as indicated to evaluate miR-221 and miR-
222 expression. The reported data are normalized to RNU6B and are
representative of 5 experiments (***P<0.001 miR-221 and miR-222
expression in UnAG-treated SCs+anti–miR-221/222 vs UnAG-
treated SCs+anti-miR neg ctrl). qRT-PCR indicates quantitative real-
time PCR; miR, microRNA; SC, satellite cell; UnAG, unacylated
ghrelin.
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Figure 17. In vivo miR-221/222 expression recapitulates UnAG effects. A, SCs recovered from normo-perfused muscles were treated for
72 hours with the indicated stimuli and subjected to in vitro ischemia. SOD-2 content was evaluated in SCs transfected for the past 48 hours with
scramble or SOD-2 siRNA. Protein level was normalized to a-actin. The results are representative of 3 different experiments performed in triplicate
(***P<0.001 SOD-2 siRNA- vs scramble-transfected SCs). B, miR-221/222 expression was evaluated by qRT-PCR on SCs silenced for SOD-2 and
subjected to in vitro ischemia. Data normalized to RNU6B are representative of 4 different experiments performed in triplicate (***P<0.001
UnAG-treated SCs transfected with scramble vs saline-treated cells; ***P<0.001 UnAG-treated SCs transfected with SOD-2 siRNA vs UnAG-
treated SCs transfected with scramble). C, Representative hematoxylin and eosin–stained sections of ischemic and normo-perfused (normal)
muscles of mice injected with pre-miR negative control (neg ctrl) or with pre-miR-221/222, killed at day 7 post surgery. Scale bar: 80 lm (920
magnification). Inset shows myofibers at higher magnification; green arrows indicate regenerating myofibers, characterized by central nucleus
location at day 7 in mice expressing pre–miR-221/222. D, Foot damage score of treated mice evaluated for the indicated times. Data are
expressed as meanSEM (n=5) (***P<0.001 ischemic limb of pre–miR-221/222–treated vs pre-miR neg ctrl–treated mice). E, Percentage
(meanSEM) of regenerating fibers in pre-miR neg ctrl or pre–miR-221/222–treated mice after ischemia (n=5) (***P<0.001 ischemic muscles of
pre–miR-221/222–treated vs pre-miR neg ctrl–treated mice at day 7; normal muscles vs ischemic muscles of treated mice). F, miR-221/222
expression was evaluated by qRT-PCR on SCs recovered from mice treated as indicated 7 days after ischemia. Data normalized to RNU6B are
representative of 5 different experiments (***P<0.001 miR-221/222 expression in ischemic SCs from pre–miR-221/222–treated vs pre-miR neg
ctrl–treated mice). G, MyoD, p-p38/MAPK, myogenin and Pax-7 content was analyzed in SCs recovered from mice treated as above and
normalized to tubulin content. The results are representative of 5 different experiments (***P<0.001 MyoD, and myogenin content in ischemic
SCs from pre–miR-221/222–treated vs pre-miR neg ctrl mice; *P<0.05 p-p38/MAPK content in ischemic SCs from pre–miR-221/222–treated vs
pre-miR neg ctrl mice). qRT-PCR indicates quantitative real-time PCR; miR, microRNA; SC, satellite cell; SOD-2, superoxide dismutase-2; UnAG,
unacylated ghrelin.
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In addition to precise transcriptional regulation,9 muscle
regeneration requires posttranscriptional regulation of genes
involved in cell-cycle progression.10–12,59 The microRNAs
miR-221 and miR-222 have been described as potent
regulators of progression through the G1/S phase via
posttranscriptional regulation of the Cip/Kip family members
p27Kip1 and p57Kip2 in various malignancies,60 in endothelial
cells,40 and in myoblasts.14 For instance, Cardinale et al13
have demonstrated that, in both quail embryo myoblasts and
C2C12 cells, miR-221/222 control the expression of p27
Kip1
but not that of p57Kip1 during differentiation and maturation
of skeletal muscle cells. In our study, only p57Kip2 was
downregulated in SCs recovered from ischemic muscles of
UnAG-treated animals, and its expression was correlated with
the expression of miR-221/222. After proliferation, the
majority of SCs enter the myogenic differentiation program,
a process that requires changes in the cell-cycle machinery.
It has been shown that an impaired p27Kip1 accumulation
resulting from miR-221/222 overexpression13 leads to a
transient delay in the exit from the cell cycle in vitro and that
knock down of p27Kip1 and p57Kip2 is sufficient to prevent
myogenesis.61 This suggests that in our in vivo ischemia
model, the balance between the levels of p27Kip1 and p57Kip2
might be crucial for completion of the regenerative process.
Moreover, given that SC fate in vivo is more complex than
expected in vitro, alternative mechanisms could account for
our results. Accumulating evidence indicates that a number
of miRs, either directly or indirectly, control the transition
from cell-cycle progression to the induction of cell-cycle
quiescence and differentiation in skeletal muscles.62 Our
findings that anti–miR-221/222 prevent UnAG-mediated
expression of transcriptional factors associated with myo-
genesis and that in vivo administration of pre–miR-221/222
induces skeletal muscle regeneration do not exclude the
possibility that other miRs, or miRs under the control of miR-
221/222, could participate and finely regulate the entire
process. Finally, our finding that miR-221/222 expression in
response to UnAG treatment is under the control of SOD-2
suggests that, in addition to fine-tuning the response to
specific metabolic demands, mitochondrial enzymes may also
actively participate in tissue repair following ischemia by
regulating miR-221/222 expression (see the proposed model
in Figure 18).
Although UnAG effects can be recapitulated in the in vitro
model of ischemia, it is likely that the ischemic microenvi-
ronment in vivo itself influences the response to UnAG. It is
Figure 18. Schematic representation of the molecular events activated by UnAG treatment following ischemia. Left: SC proliferation in
response to muscle damage. Following muscle damage in response to microenvironmental stimuli, quiescent SCs undergo proliferation and
differentiation to form new myofibers. Right: Proposed mechanism of UnAG action in response to ischemia. Following ischemic damage,
quiescent SCs, protected from ROS generation by UnAG-mediated SOD-2 expression and miR-221/222–driven p57Kip2 posttranscriptional
regulation, proliferate. As UnAG treatment leads to skeletal muscle regeneration, we hypothesize that the balance between p27Kip1 and p57Kip2
content or, alternatively, the expression of miRs different from miR-221/222 or regulated by miR-221/222 might be relevant for the entire
regenerative process. FGF indicates fibroblast growth factor; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor-1; miR, microRNA;
ROS, reactive oxygen species; SC, satellite cell; SOD-2, superoxide dismutase-2; UnAG, unacylated ghrelin.
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known that a number of soluble factors are released locally
and actively participate in muscle regeneration and hypertro-
phy.63,64 Consistent with data obtained by Porporato et al,27
in our model, UnAG treatment led to skeletal muscle
regeneration but not hypertrophy (data not shown). Likewise,
the numbers of infiltrating CD68+ cells, which are known to
act as mitogens for SCs,65 were decreased in muscles from
UnAG-treated animals. Finally, even by interfering with
hepatocyte growth factor–mediated activity, UnAG still
retained the ability to direct myoblast expansion in ischemic
conditions. Taken together, these data suggest that although
the release of soluble molecules into the ischemic microen-
vironment might contribute to the entire regenerative pro-
cess, UnAG acts independently of hepatocyte growth factor to
drive SC expansion after ischemia.
In summary, our data demonstrate that, unlike AG, UnAG
exerts antioxidant effects and promotes skeletal muscle
regeneration on ischemia. Efforts should now be made to
further investigate the therapeutic potential of UnAG-related
peptides or pre–miR-221/222 for the treatment of PAD and
other conditions in which ROS scavenging and antioxidant
efficiency is required.
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